BCYC's Quality Score rose 1 point on Tue, Nov 10, to -3.
Follow BCYC's trial news. Pro members can get an alert when Bicycle Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 94% over five years while the S&P 500 rose 72%.
“The decrease in collaboration revenue of $9.1 million was primarily due to the termination of our collaboration programs with Genentech and Novartis.”
| Since its Nov 2021 high | Down 94% |
| Latest filing | 8-K, Oct 29 |
After its last 4 reports it closed +0.6% on average, higher 2 of 4 times.
The company says its cash lasts into 2030 (8-K, Oct 29).
No shelf registration or at-the-market program on file in the last three years.
Chief Operating Officer Jennifer Scott Perry sold 356 shares on Oct 5, under a planned sale. 22 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Poorfor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means
BCYC is #202 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 202 |
Expected to report Tue Mar 16, before the open (in 126 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $0.15 a share, from $0.85.
“The decrease in cash and cash equivalents is primarily due to cash used in operations, including cash payments for clinical program activities.”
BCYC's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“Cash and cash equivalents of $469.9 million as of September 30, 2026, with expected cash runway into 2030”
From its results filing (SEC filing · Oct 29)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Oct 29, 2026 | +1.0% | -1.6% | -4.1% |
| Jul 30, 2026 | 0.0% | +3.9% | +2.9% |
| Apr 30, 2026 | -1.5% | -0.2% | +8.9% |
Sales grew in six of the last seven years, to $72.6M in 2025. It lost money in each of the eight years.
RSI 50.0, MACD above signal, below both averages. Not scored.
5 insiders sold $112K across 17 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
“The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products.”
BCYC scores -3 today, which Breakaway calls Poor. It is #202 of 281 in Biotech by Quality Score, with 3 of 14 chart checks firing. Down 94% over five years while the S&P 500 rose 72%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
BCYC scores -3 today, which Breakaway calls Poor (below zero). That is #202 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind BCYC's -3.
5 insiders sold $112K across 17 filings in the last 6 months. No open-market buys on record. The newest is Kevin Lee, Chief Executive Officer, who sold $21K on Oct 2. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free for 24 hours. No account. No card. Then keep going with a free account.